CMOs Ratchet up use of Single-Use Devices to Improve Performance - Single-use systems continue to gain traction among biomanufacturers, especially CMOs. - BioPharm International

ADVERTISEMENT

CMOs Ratchet up use of Single-Use Devices to Improve Performance
Single-use systems continue to gain traction among biomanufacturers, especially CMOs.


BioPharm International
Volume 24, Issue 11, pp. 27-30

WHERE HAVE SINGLE-USE SYSTEMS PROVED BENEFICIAL?


Figure 2: Select activities implemented to speed drug development timelines identified by biomanufacturers versus CMOs.
BioPlan evaluated 15 activities manufacturing organizations have implemented over the past year to specifically speed drug-development timelines. The use of more disposables and single-use devices in manufacturing took the top slot, with 40.8% of respondents. Following disposables was the use of more "platform'" downstream processes, at 37.7%. Analysis of those activities showed that there was a cluster of mid-level activities that sped drug-delivery times. These included activities such as using "platform" cell lines, improved in-process monitoring, use of "design of experiment" methods, and use of better chromatography resins. At the bottom of the attributes was "use of different expression systems." However, because expression systems are typically a one time decision, this is not unexpected.

Comparing biomanufacturers to CMOs, BioPlan found that for CMOs the number one activity implemented to speed drug development timelines was the use of more disposables and single-use devices in manufacturing (72% vs. 42% for biomanufacturers).


Survey methodology
Trends in the time required for product development and approval are closely related to productivity and cost concerns. This year, the survey showed that acceptance of single-use devices is also being used as a cost-cutting action. Of 212 respondents to this question, 35.4% accepted single-use (disposable) systems into clinical manufacturing operations to cut costs, while 19.3% accepted single-use systems into commercial manufacturing operations for the same reason.

PRIMARY REASONS FOR INCREASING USE OF DISPOSABLES

BioPlan identified reasons for the increasing trend towards use of disposable and single-use system components. Single use disposable systems can provide cost savings, and sometimes these savings can be substantial compared with fixed stainless steel systems, particularly with regard to larger systems. Indeed, as shown above, biomanufacturers are accepting single-use systems as a cost-cutting mechanism, and according to BioPlan's data, almost 58% of respondents indicate that using disposables to lower annual costs is a "very important" attribute.

However, as in previous years, direct cost reductions do not appear to be among the most widespread ("important" or "very important") factors to these decision-makers. As in earlier years, the data indicate that disposable systems users are more concerned about factors that will save time, reduce risks, and accelerate campaign turnaround. Increasingly, they are also interested in reducing capital equipment.

The primary reasons biopharmaceutical developers and CMOs use these products are to:

  • Eliminate cleaning requirements (90.2% indicating "important" or "very important")
  • Reduce capital investment in facility and equipment (85%)
  • Reduce time to get facility up and running (85%)
  • Decrease campaign turnaround time (81.7%).

A significant shift is the focus on reducing capital investment in facility and equipment. Despite the loosening of budgetary constraints, end-users are increasingly interested in seeing how disposable systems can help them avoid capital investments in manufacturing.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here